ClinicalTrials.gg
RecruitingNCT07710625Updated Jul 22, 2026

"Turkish Validity and Reliability of the Heat Sensitivity Scale for Individuals With Parkinson's Disease"

An observational study in Parkinson Disease and Temperature Sensivity, sponsored by Acibadem University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Acibadem University · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
100
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 172 studies in Parkinson Disease with a site in Turkey — 50 open to participants now, 56 under way, none of them phase 3. Parkinson Disease · Turkey.

Planned enrollment
12th of 73
100 · median 61
Started
2026
with 28 others
Observational
73 of 172
23 open now
Primary completion
2026-12
later than 37 of 55 live
Registered
164th of 172
by date
Lead sponsor
5 of 172
Acibadem University

Among the 172 studies in Parkinson Disease with a site in Turkey, this one is the 12th largest by planned enrollment of the 73 observational ones that give a count, is one of 29 that started in 2026, is one of 73 observational ones, reaches primary completion later than 37 of the 55 other live ones, and was the 164th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

50 of the 172 studies in Parkinson Disease with a site in Turkey are open now. Recruiting first, the newest first:

44 more — sign in →

All 50 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Parkinson Disease with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this study is to examine the validity and reliability of the Turkish version of the Heat Sensitivity Scale in individuals with Parkinson's disease. This cross-sectional methodological study will evaluate the psychometric properties of the scale, including internal consistency, test-retest reliability, and construct validity, in order to provide a valid and reliable tool for assessing temperature sensitivity in Turkish-speaking individuals with Parkinson's disease.

03

Conditions studied

  • Parkinson Disease
  • Temperature Sensivity

Browse trials for

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of individuals with clinically diagnosed Parkinson's disease (Hoehn and Yahr stage 1-3), aged between 40 and 85 years, with adequate cognitive function (MMSE ≥ 24). Participants will be recruited from patients attending the Movement Disorders Outpatient Clinic of the Neurology Department. The study population represents ambulatory individuals with mild to moderate disease severity suitable for comprehensive biopsychosocial assessment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Parkinson's disease
  • Hoehn and Yahr stage 1-3
  • Age between 40 and 85 years
  • score ≥ 24
  • Sufficient cognitive and communication ability to complete the assessments
  • Attendance at the Movement Disorders Outpatient Clinic of the Neurology Department
  • Willingness to participate and provide written

Exclusion criteria

Exclusion Criteria:

  • Presence of a major psychiatric disorder, such as major depressive disorder or a psychotic disorder
  • Diagnosis of advanced dementia
  • Presence of an uncontrolled systemic chronic disease, such as uncontrolled diabetes mellitus or hypertension
  • Presence of a severe cardiovascular or respiratory condition
  • Presence of an additional orthopedic or neurological condition that may affect assessment performance
  • Severe visual or hearing impairment that may interfere with the assessments
  • Inability to cooperate adequately during the assessments
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Heat Sensitivity Scale Total Score

    Heat sensitivity will be assessed using the Turkish version of the Heat Sensitivity Scale in individuals with Parkinson's disease. The scale evaluates symptoms related to heat sensitivity and their impact on daily life. The total score ranges from 29 to 116, with higher scores indicating greater heat sensitivity-related problems and therefore a worse outcome. Psychometric properties, including internal consistency, test-retest reliability, and construct validity, will be analyzed.

    Time frame: Baseline (at the time of questionnaire administration)

Secondary outcomes

  1. Parkinson's Disease Questionnaire-39 (PDQ-39) Total and Subscale Scores

    Quality of life will be assessed using the Parkinson's Disease Questionnaire-39 (PDQ-39), a validated self-report measure specific to Parkinson's disease. The questionnaire consists of 39 items across 8 domains, including mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. Scores can be transformed to a 0-100 scale, with higher scores indicating worse quality of life. PDQ-39 scores will be used to evaluate the construct validity of the Turkish version of the Temperature Sensitivity Scale.

    Time frame: Baseline (at the time of questionnaire completion)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 17, 2026
StartActual
May 25, 2026
Primary completionEst.
Dec 25, 2026
CompletionEst.
May 25, 2027
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07710625
Responsible party
Nuray Alaca (Assoc. Prof. Nuray Alaca, Acibadem University) — Principal investigator
First posted
Jul 17, 2026
Start date
May 25, 2026
Primary completion
Dec 25, 2026 (estimated)
Completion
May 25, 2027 (estimated)
Last update
Jul 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion